ReviewFrontiers in pharmacology2021
The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Guideline
- Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial.RMD open · 2025Trial
- Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study.Immunologic research · 2023Trial
- Molecular Insights into Oral Manifestations in Sjögren's Disease.International journal of molecular sciences · 2026Review
- Patient-Reported Symptoms Versus Clinician-Measured Signs to Distinguish Sjogren's in Patients With Dry Eye.Translational vision science & technology · 2026Article
- Prognostic benefit of immunosuppressive agents in primary Sjögren's syndrome patients with hypergammaglobulinemia.Frontiers in immunology · 2026Article
- Risk of venous, arterial, and rare thrombotic events in adults with Sjögren's disease: a systematic review and meta-analysis.Reumatologia · 2026Review
- Role of antimalarials in lupus nephritis: a narrative review.Clinical rheumatology · 2025Review
- Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren's syndrome: a real-world Study.Clinical rheumatology · 2025Article
- The Role of Hydroxychloroquine in the Management of Rheumatic Disorders: A Comprehensive Review.Basic & clinical pharmacology & toxicology · 2025Review
- Hydroxychloroquine: A double‑edged sword (Review).Molecular medicine reports · 2025Review
- The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.Arthritis research & therapy · 2025Article
- Increased risk of dementia in patients with primary Sjogren's syndrome: a nationwide population-based cohort study.The Korean journal of internal medicine · 2025Article
- A Randomised Double-Blind Placebo-Controlled Clinical Trial of Fish Oil (Omega-3) in Sjögren's Syndrome Patients in Erbil-Iraq.Mediterranean journal of rheumatology · 2025Article
- Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren's syndrome.Frontiers in medicine · 2025Article
- FatiguE in Sjögren's Syndrome: a randomised controlled trial of cOmbined Non-phArmacological therapeutic strategies (FESSONA).BMJ open sport & exercise medicine · 2025Article
- STING pathways and Sjögren's syndrome: Exploration from mechanism to treatment.Frontiers in immunology · 2025Review
- Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndrome.Human vaccines & immunotherapeutics · 2024Article
- G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.Acta pharmacologica Sinica · 2024Article
- The Proportion of Ocular Involvement and Characteristics of Dry Eye Parameters in Primary Sjögren Syndrome Referred from the Rheumatology Department.Korean journal of ophthalmology : KJO · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.